International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb ,
The aging of the immune system, Handbook of Systemic Autoimmune Diseases, pp.295-306, 2006. ,
The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis Antiphospholipid syndrome Mechanistic view of risk factors for venous thromboembolism, Manoussakis, A. G. Tzioufas, M. P. Silis, P. J. Pange, J. Goudevenos, and H. M, pp.13-34, 2009. ,
The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies, Clin. Exp. Immunol. J. Rheumatol, vol.69, issue.16 5, pp.557-565, 1987. ,
PREVALENCE OF SELECTED AUTOANTIBODIES IN DIFFERENT ELDERLY SUBPOPULATIONS, Rheumatology, vol.33, issue.12, pp.1121-1124, 1994. ,
DOI : 10.1093/rheumatology/33.12.1121
Antiphospholipid Syndrome in the Elderly: Caution, Circulation, vol.97, issue.22, pp.2195-2196, 1998. ,
DOI : 10.1161/01.CIR.97.22.2195
Prevalence and disease associations of certain autoantibodies in elderly patients, Clin. Investig. Med. Médecine Clin. Exp, vol.21, issue.1, pp.4-11, 1998. ,
Anticardiolipin antibodies in two elderly subpopulations, Lupus, vol.317, issue.289, pp.482-485, 1995. ,
DOI : 10.1002/ddr.430150207
Anticardiolipin Antibodies and Physical Disability in the Elderly, Annals of Internal Medicine, vol.126, issue.12, p.1003, 1997. ,
DOI : 10.7326/0003-4819-126-12-199706150-00024
High Prevalence of Protein-Dependent and Protein-Independent Antiphospholipid and Other Autoantibodies in Healthy Elders, Thrombosis Research, vol.99, issue.2, pp.129-133, 2000. ,
DOI : 10.1016/S0049-3848(00)00243-7
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients, Ann. Rheum. Dis, vol.68, issue.9, pp.1428-1432, 2009. ,
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Phospholipid Project Group (European Forum on Antiphospholipid Antibodies) Ann. Rheum. Dis, vol.18, 2008. ,
Significance of persistent antiphospholipid antibodies in the elderly, J. Rheumatol, vol.33, issue.8, pp.1559-1562, 2006. ,
Antiphospholipid syndrome Lessons from the 'Euro-Phospholipid' project Anti-beta 2 glycoprotein I antibodies in centenarians Current concepts on the pathogenesis of the antiphospholipid syndrome Pathogenesis of antiphospholipid syndrome: understanding the antibodies Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection The antiphospholipid syndrome, 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome, pp.1019-1027, 1992. ,
The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome Antiphospholipid antibodies during infectious mononucleosis and their long term clinical significance Definition and significance of high positivity aCL ELISA Antiphospholipid antibodies and infections Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile De Groot, and Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis [40] European Genetics Foundation, Cardiovascular Disease Educational and Research Trust, International Union of Angiology Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence Renal involvement in primary antiphospholipid syndrome Shoenfeld, and Catastrophic Antiphospholipid Syndrome Registry Project Group Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines Valvular heart disease in antiphospholipid syndrome Renal involvement in antiphospholipid syndrome Central nervous system involvement in the antiphospholipid (Hughes) syndrome The epidemiology of heart failure: the Framingham Study Probability of stroke: a risk profile from the Framingham Study Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a 'set up' for vascular disease Venous thrombosis in the elderly: incidence, risk factors and risk groups, Dermatologic manifestations of the antiphospholipid syndrome Médecine Interne Fondée Par Société Natl. Francaise Médecine Interne Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study) Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study53] M. J. Engbers, A. van Hylckama Vlieg, and F. R. Rosendaal54] L. Weingarz, J. Schwonberg, M. Schindewolf, C. Hecking, pp.752-763, 1950. ,
Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry, Br. J. Haematol, vol.163, issue.5, pp.655-665, 2013. ,
Prevalence of established risk factors for venous thromboembolism according to age The epidemiology of the antiphospholipid syndrome: who is at risk?, J. Vasc. Surg. Venous Lymphat. Disord. Curr. Rheumatol. Rep, vol.2, issue.3 4, pp.131-139, 2001. ,
Incidence of a first thromboembolic event in asymptomatic carriers of highrisk antiphospholipid antibody profile: a multicenter prospective study Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: 'Pros' and 'Cons, Blood Autoimmun. Rev, vol.118, issue.11 8, pp.4714-4718, 2011. ,
systemic lupus erythematosus: A systematic review and meta-analysis Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis, Autoimmun. Rev. Blood Lupus, vol.13, issue.6 5, pp.595-608, 1997. ,
Anti??2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study) Antiphospholipid antibodies ? We are not quite there yet Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study A prospective study of antibodies to ?2-glycoprotein I and prothrombin, and risk of thrombosis, [68] K. Devreese, K. Peerlinck, and M. F. Hoylaerts Ulcova-Gallova, K. Mertens, and P. G. de Groot, pp.15-22, 1998. ,
The presence of IgG antibodies against ?2- glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, J. Thromb. Haemost. J. Thromb. Haemost, vol.3, issue.6, pp.1160-1165, 2005. ,
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody???positive individuals, Arthritis & Rheumatism, vol.113, issue.7, pp.237-242, 2007. ,
DOI : 10.1136/bmj.309.6963.1215
Tincani, and Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study, [76] S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. A. Khamashta, and M. L, pp.1083-1086, 2011. ,
Atherosclerosis--an inflammatory disease The immune response in atherosclerosis: a doubleedged sword, GAPSS: the Global Anti-Phospholipid Syndrome Score, pp.1397-1403, 1999. ,
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus Dendritic cells: An important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review, Mänttäri, V. Manninen, L. Tenkanen, M. Puurunen, K. Aho, and T, pp.2331-2337, 2001. ,
Anticardiolipin Antibodies and Recurrent Coronary Events A Prospective Study of 1150 Patients A005 Augmentation de la rigidité artérielle associée aux anticorps antiphospholipides [Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy) Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone Le syndrome des antiphospholipides en 2012 : son hétérogénéité impose une prise en charge personnalisée Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis, Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men. [91] J. A. Girón-González, E. García del Río, C. Rodríguez, J. Rodríguez-Martorell, and A, pp.23-27, 1995. ,
Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety APS ACTION-- AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking Atherosclerosis in systemic lupus erythematosus Potential use of statins in the treatment of antiphospholipid syndrome, 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends Core Team, R: A language and environment for statistical computing Modeling Survival Data: Extending the Cox Model. Terry M. Therneau and Patricia M. Grambsch, pp.1560-1567, 2000. ,
The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, Price: $69.95. [102] G. Finazzi, V. Brancaccio, M. Moia, N. Ciaverella, M. G. Mazzucconi, P. C. Schinco, M, pp.2053-2054, 1989. ,
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry Tripodi, and Participating Centres of Italian Federation of Thrombosis Centres (FCSA) Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples Antiphospholipid antibodies: evaluation of the thrombotic risk Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus Solid cancer, antiphospholipid antibodies, and venous thromboembolism Diagnosis and classification of the antiphospholipid syndrome, Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients, pp.530-536, 1996. ,